AGP Executive Report
Last update: 8 hours agoMedical & Consumer Growth: CVS lifted its 2026 profit outlook after a stronger Q2, helped by better drug mix and Aetna Star-rating bonuses, and it’s rolling out $29 MinuteClinic visits for weight-loss prescriptions tied to Lilly and Novo meds. Healthcare Demand Forecasts: Persistence Market Research projects rapid expansion across biomaterials (to $764.1B by 2033), preventive medicine (to $730.3M by 2033), and diagnostic enzymes (to $7.6B by 2033). AI & Enterprise Tech: Circana says U.S. B2B tech revenue rose 10% in H1 2026, with growth expected to moderate in H2; TransUnion finds a “confidence-readiness paradox” as marketers invest in AI but lack data/process foundations. Defense & Drones: ABI Research forecasts small UAS growth at 8% CAGR to 2035, with military procurement still the biggest driver while commercial use expands. EV Momentum: India’s EV market is projected to hit $191.04B by 2034, supported by charging buildout and battery growth; UK new-car registrations rose 11.7% in July with electrified demand driving the record. Markets & Corporate Signals: NYT shares fell after slower digital subscriber growth and a weaker digital revenue forecast; Seres accelerated a buyback but its stock remains range-bound, highlighting investor skepticism. Energy/Materials Micro-Trends: Malaysia rubber prices were mixed as EV demand and stable U.S. conditions offset higher inventories and seasonal production.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
